Controlled trial of a new dosage form of carbenoxolone (Pyrogastrone) in the treatment of reflux esophagitis.

Abstract

A new preparation combining carbenoxolone sodium with alginate antacid (Pyrogastrone), taken for 8 weeks, was compared with alginate antacid alone (Gaviscon-like) in a controlled double-blind study in 37 patients with endoscopically proved reflux esophagitis. Complete remission or persistence of only minimal symptoms was obtained in 89%, and esophageal ulcer healing was achieved in 100% of subjects taking Pyrogastrone, compared with only 50% (P less than 0.025) and 33% (P equal 0.02), respectively, on control treatment. Complete endoscopic healing or persistence of only minimal inflammation was seen in 95% on Pyrogastrone and 67% of controls (P less than 0.05). Mild biochemical and clinical changes were noted in 9 of 19 patients on Pyrogastrone and 6 of 18 on the control drug, but none required treatment or alteration in regime. Thus Pyrogastrone is more effective in the treatment of reflux esophagitis than the most efficacious compound in current use.

• Authors: P I Reed, W A Davies
• Journal: The American journal of digestive diseases (Am J Dig Dis) Vol. 23 Issue 2 Pg. 161-5 (Feb 1978) ISSN: 0002-9211 [Print] United States
• PMID: 341689 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Alginates
• Antacids
• Triterpenes
• Carbenoxolone

Topics

• Adult
• Aged
• Alginates (therapeutic use)
• Antacids (therapeutic use)
• Carbenoxolone (adverse effects, blood, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Esophageal Diseases (drug therapy)
• Esophagitis, Peptic (drug therapy, pathology)
• Esophagoscopy
• Esophagus (pathology)
• Female
• Humans
• Male
• Middle Aged
• Triterpenes (therapeutic use)
• Ulcer (drug therapy)